Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
about
Intermediate acting versus long acting insulin for type 1 diabetes mellitusEfficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysisCardiovascular effects of basal insulinsClinical experience with insulin glargine in type 1 diabetes.Glargine safety, diabetes and cancer.Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis.Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value.Comparison of Optimised MDI versus Pumps with or without Sensors in Severe Hypoglycaemia (the Hypo COMPaSS trial)Systemically modeling the dynamics of plasma insulin in subcutaneous injection of insulin analogues for type 1 diabetes.Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study.Long-Acting Insulin Analogues for the Treatment of Diabetes Mellitus: Meta-analyses of Clinical OutcomesInsulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus.Institution of basal-bolus therapy at diagnosis for children with type 1 diabetes mellitus.MATHEMATICAL MODELS OF SUBCUTANEOUS INJECTION OF INSULIN ANALOGUES: A MINI-REVIEWSevere hypoglycaemia in type 1 diabetes mellitus: underlying drivers and potential strategies for successful prevention.Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice.Number-Based Approach to Insulin Taxonomy.United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes.[Use of insulin glargine in type 1 diabetes children with less than eight years old].Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells.The utility of insulin glargine in the treatment of diabetes mellitus.Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy.Treatment with insulin glargine reduces asymptomatic hypoglycemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetes.Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials.A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus.
P2860
Q24241828-E2C180BC-C467-472F-AB3F-782344584D0EQ24656013-0FBF1496-2946-4334-86D5-61DE0D11F673Q26800249-D6FD7DAE-6FB4-4B70-AA1C-2EB356228600Q34296834-EE47BC10-B18A-47DC-A974-6D33795862E7Q34326924-1B1A1C46-E708-482B-B0B4-44A9FE7DC0EAQ34349437-0F9336C9-DFD3-40AE-81ED-64F49D3B2DC3Q34449820-53D285AE-4E2B-47EF-8729-F9E7A3D07FF2Q34511505-C4137986-5A36-494B-B96D-BBF8D5644990Q34537345-716C14DD-51BA-43DB-B911-31D4161340B5Q35921474-EA27C6F3-4B8F-4A64-880D-3AF408027328Q36137731-1141F615-21E3-45C9-8412-829564ABEA08Q36521871-A4660DC3-5DE9-441F-86D6-80C381533B02Q37186391-F8314733-57BA-4002-B871-6699FCF9EE58Q37875678-F727CFDF-F974-4A8C-9D61-DE10FEA71122Q38159475-2A9F47DC-09A9-4BDA-8671-13776434C784Q38176677-9A554AA9-524B-4D01-A8FA-35AFC84921A3Q38583002-729C9558-7B55-48B4-987B-18E7FE639366Q38689189-FEBAF6C4-5C6A-4BDD-A6AF-C4CD66C8D5CAQ43247406-F1DADBB3-547F-4B2C-8897-3A6EED09DB3AQ44726965-7055E5A3-01A5-4DE3-A44D-3C5EB2F5DE4DQ44955647-E3163AE4-AC48-4C95-B959-E1AE946BA2ACQ46707992-98D508F5-1327-4F67-BA4E-EB7604806059Q51470109-530DDF95-A841-4572-8989-D0C4D6B4349AQ52591845-F8A83939-3C67-49FA-ACB8-75AC856FFB71Q55162068-C820C04A-2D40-4623-9744-456F59058E2D
P2860
Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Intensive replacement of basal ...... insulin at dinner or bedtime.
@en
Intensive replacement of basal ...... insulin at dinner or bedtime.
@nl
type
label
Intensive replacement of basal ...... insulin at dinner or bedtime.
@en
Intensive replacement of basal ...... insulin at dinner or bedtime.
@nl
prefLabel
Intensive replacement of basal ...... insulin at dinner or bedtime.
@en
Intensive replacement of basal ...... insulin at dinner or bedtime.
@nl
P2093
P921
P1433
P1476
Intensive replacement of basal ...... insulin at dinner or bedtime.
@en
P2093
Carmine Fanelli
Elisabetta Torlone
Emanuela Costa
Francesca Porcellati
Geremia B Bolli
Luciano Scionti
Simone Pampanelli
P304
P356
10.2337/DIACARE.26.5.1490
P407
P577
2003-05-01T00:00:00Z